Drug
Efgartigimod OR Efgartigimod Ph20
Efgartigimod OR Efgartigimod Ph20: highest development phase Phase 2/3, developed by Argenx. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2/3
- Developer
- Argenx
Trials
| Drug | Phase | Indication |
|---|---|---|
| Efgartigimod IV or Efgartigimod PH20 SC NCT05374590 | Phase 2/3 | Generalized Myasthenia Gravis |
Latest
No recent events.
Follow Efgartigimod OR Efgartigimod Ph20 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.